View in EDS HTML Full Text PDF Full Text

Clinical efficacy of casirivimab and imdevimab in preventing COVID-19 in the Omicron BA.5 subvariant epidemic: a retrospective study.

Saved in:
Bibliographic Details
Title: Clinical efficacy of casirivimab and imdevimab in preventing COVID-19 in the Omicron BA.5 subvariant epidemic: a retrospective study.
Authors: Ohtani M; Department of Pharmacy, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan. mariko.ootani@med.toho-u.ac.jp.; Department of Infection Control and Prevention, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan. mariko.ootani@med.toho-u.ac.jp., Yokoo T; Department of Pharmacy, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Miyazaki T; Department of Infection Control and Prevention, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.; General Medicine and Emergency Center, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Yasuda H; Department of Pharmacy, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Nishikawa E; Department of Infection Control and Prevention, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Tomida M; Department of Infection Control and Prevention, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Tsukada M; Department of Infection Control and Prevention, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Sato E; Department of Nursing, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Hirayama S; Department of Pharmacy, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Murakami H; Department of Infection Control and Prevention, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.; Department of Clinical Laboratory, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Yoshizawa S; Department of Clinical Laboratory, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.; Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-Nishi, Ota-Ku, Tokyo, 143-8540, Japan., Matsumoto T; Department of Pharmacy, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan., Tateda K; Department of Infection Control and Prevention, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.; Department of Clinical Laboratory, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.; Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-Nishi, Ota-Ku, Tokyo, 143-8540, Japan.
Source: Journal of pharmaceutical health care and sciences [J Pharm Health Care Sci] 2025 Oct 27; Vol. 11 (1), pp. 94. Date of Electronic Publication: 2025 Oct 27.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101672177 Publication Model: Electronic Cited Medium: Print ISSN: 2055-0294 (Print) Linking ISSN: 20550294 NLM ISO Abbreviation: J Pharm Health Care Sci Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2055-0294
DOI:10.1186/s40780-025-00501-x